TNF inhibitors should be used in patients with heart failure only after consideration of other treatment options.
TNF inhibitors are contra-indicated in patients with a personal or family history of multiple sclerosis or demyelinating disease.
TNF inhibitors should not be administered to patients with moderate to severe heart failure (New York Heart Association Functional Class III/IV).
Adalimumab-atto (Amjevita) is biosimilar to Adalimumab (Humira). Approved 09/23/2016
Adalimumab-adbm (Cyltezo) is biosimilar to Adalimumab (Humira). Approved 08/25/2017
Adalimumab-adaz (Hyrimoz) is biosimilar to Adalimumab (Humira). Approved 10/30/2018
Adalimumab-bwwd (Hadlima) is biosimilar to Adalimumab (Humira). Approved 07/23/2019
Adalimumab-afzb (Abrilada) is biosimilar to Adalimumab (Humira). Approved 11/15/2019
Adalimumab-fkjp (Hulio) is biosimilar to Adalimumab (Humira). Approved 07/06/2020
Adalimumab-aqvh (Yusimry) is biosimilar to Adalimumab (Humira). Approved 12/17/2021
AAdalimumab-aacf (Idacio) is biosimilar to Adalimumab (Humira). Approved 12/13/2022
Adalimumab-ryvk (Simlandi) is biosimilar to Adalimumab (Humira). Approved 02/23/2024
Adalimumab-aaty (Yuflyma) is biosimilar to Adalimumab (Humira). Approved 05/23/2023
- TRADE NAMES: Amgevita (Amgen); Amjevita (Amgen); Humira (AbbVie); Hyrimoz (Sandoz); Idacio (Fresenius Kabi USA); Imraldi (Biogen); Yuflyma (Celltrion)
- INDICATIONS: Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis
- CLASS: Anti-Tumor Necrosis Factor-alpha (TNF-α antagonist), Antipsoriatic agent, Biologic, Biologic disease-modifying antirheumatic drug (bDMARD), Cytokine inhibitor, Disease-modifying antirheumatic drug (DMARD), Monoclonal antibody
- HALF-LIFE: 10–20 days
SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of adalimumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/28/2025
